CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02158858
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:12.613943+00:00
- Published At
- 2025-10-08T00:00:00+00:00
- Record Updated At
- 2025-10-08
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Myelofibrosis", "Leukemia, Myelocytic, Acute", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelodysplastic Syndrome (MDS)", "Preleukemia", "Primary Myelofibrosis", "Myeloproliferative Disorders", "Bone Marrow Disease", "Hematological Disease", "Precancerous Conditions", "Neoplasms", "Leukemia", "Neoplasms by Histologic Type", "Essential Thrombocytosis"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-10-08"- protocolSection.identificationModule.nctId
"NCT02158858"- protocolSection.identificationModule.officialTitle
"A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.